A Phase III Study to Evaluate the Safety, Efficacy and Pharmacokinetics/Pharmacodynamics of BAYQ3939 in Patients With Bacterial Pneumonia

Inclusion Criteria: * Males and non-pregnant, non-lactating females with written informed consent, 20 years of age or older. * Within 48 hours prior to the first study drug administration, all patients should have the pathogens identified with appropriate specimens (e.g., sputum, tracheal aspirate, bronchoalveolar lavage \[BAL\], protected brushing specimen \[PBS\]), or should have appropriate specimens highly likely to identify the pathogens sampled. (However, the patients with Legionellosis is enrolled when the test of Legionella antigen is positive.) * The following severe bacterial pneumonia meeting the diagnostic criteria of pneumonia or secondary infection of chronic respiratory disease * Severe pneumonia * Community-acquired pneumonia: PORT score III, IV or V * Hospital-acquired pneumonia \[HAP\]-Group B and with a low risk for multidrug-resistant pathogens * Patients with \[HAP\]-Group A whose pathogen is suspected to be Pseudomonas aeruginosa * Hospitalized patients with bacterial pneumonia with a poor response to other antimicrobials Note: The patients should be limited to CAP patients with PORT score III, IV or V and HAP patients with-Group A or B who don't respond to or have a poor response to other antimicrobials over 3day's treatment.2 * Secondary infection of chronic respiratory disease * Patients who are hospitalized for the treatment of secondary infection of chronic respiratory disease * Hospitalized patients with secondary infection of chronic respiratory disease with a poor response to other antimicrobials Note: The patients should be limited to secondary infection of chronic respiratory disease patients who don't respond to or have a poor response to other antimicrobials over 3day's treatment. Exclusion Criteria: * Creatinine clearance (Ccr) ≤ 30 mL/min or nephrotic syndrome * Patient with chronic treatment of immunosuppressive drug * Decompensated congestive heart failure * Subject who received more than 24 hours of an antibacterial drug for the current infection * Patient who requires Intensive Care Unit (ICU) management \[In case subjects who don't correspond to the severity for ICU management need to be admitted to ICU due to a circumstance of the site (e.g. shortage of hospital beds), those subjects shall not be excluded\] * Patients with infections other than pneumonia or secondary infection of chronic pulmonary disease * Lung abscess, or empyema * Viral, fungal, mycobacterial, or atypical pneumonia as a primary diagnosis * Known or suspected bacteremia secondary to Staphylococcus aureus * Known causative microorganisms other than indication (microorganisms) of the study drug, or positive in urinary antigen test of Streptococcus pneumonia * Infection that necessitates the use of a concomitant antibacterial agent in addition to study medication \[excluding subjects with concomitant use of long-term, low-dose macrolide for chronic respiratory diseases, sulbactam sodium/ampicillin sodium (Unasyn-S) and clindamycin (Dalacin-S)\] * Known bronchial obstruction or a history of post-obstructive pneumonia * Known primary lung cancer